Automation is not just for high-throughput screening anymore. New devices and greater flexibility are transforming what’s possible throughout drug discovery and development. This article was written by Thomas Albanetti, AstraZeneca; Ryan Bernhardt, Biosero; Andrew Smith, AstraZeneca and Kevin Stewart, AstraZeneca for a 28-page DDW eBook, sponsored by Bio-Rad. Download the… Read More
Listen to this article on the DDW Podcast: Last year a new translational research centre was established to bolster the University of Dundee’s drug discovery position. The Centre for Targeted Protein Degradation (CeTPD) would allow Professor Alessio Ciulli and colleagues to expand their pioneering work in an area that has… Read More
Artificial Intelligence (AI) is the simulation of human intelligence processes by machines, particularly computer systems, and finds itself at a climactic moment for its use within the drug discovery industry, especially as the world emerges from the Covid-19 pandemic. “Artificial intelligence and machine learning continue to play… Read More
This article is sponsored by GenScript. Integration of artificial intelligence (AI) into antibody drug discovery is occurring in phases, as AI models mature, and developers seek to compress discovery and development timelines. While increasingly iterative and feedback-driven approaches to AI-driven antibody discovery have made the process more efficient,… Read More
